BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
UCB
United Community Banks, Inc.
UCB has a slight edge over BAC overall on the model score.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
UCB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
UCB's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like UCB.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
UCB PE Valuation
UCB has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
UCB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for UCB, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
UCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.37 | +10% |
| Q2 2026 | $3.05 | +39% |
| Q1 2026 | $2.73 | +29% |
| Q4 2025 | $2.62 | +28% |
| Q3 2025 | $2.52 | +65% |
| Q2 2025 | $2.20 | +43% |
| Q1 2025 | $2.11 | +38% |
| Q4 2024 | $2.04 | +32% |
| Q3 2024 | $1.53 | -30% |
UCB earned $3.05 per share over the past year, up 39% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over UCB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
UCB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $279.3M | +7.3% |
| Q1 2026 | $276.5M | +12% |
| Q4 2025 | $278.4M | +11% |
| Q3 2025 | $276.8M | +27% |
| Q2 2025 | $260.2M | +6.1% |
| Q1 2025 | $247.7M | +3.7% |
| Q4 2024 | $250.9M | +39% |
| Q3 2024 | $217.3M | -7.4% |
UCB's revenue has grown year over year for seven quarters in a row: $279M last quarter, up 7.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 53% | +15 points |
| Q1 2026 | 39% | +2.4 points |
| Q4 2025 | 40% | +2 points |
| Q3 2025 | 43% | +15 points |
| Q2 2025 | 39% | +3.6 points |
| Q1 2025 | 37% | +3 points |
| Q4 2024 | 38% | +32 points |
| Q3 2024 | 28% | +2 points |
UCB has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
UCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $121.4M | +43% |
| Q1 2026 | $62.4M | -34% |
| Q4 2025 | $59.7M | -58% |
| Q3 2025 | $117.7M | +$119.9M |
| Q2 2025 | $84.7M | -2.9% |
| Q1 2025 | $94.3M | +26% |
| Q4 2024 | $142.6M | +1588% |
| Q3 2024 | -$2.2M | -103% |
UCB's free cash flow was $361M over the past year, up 13% from the year before. Free cash flow isn't a meaningful measure for financial services companies like UCB.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over UCB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
UCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -281K shares |
| 1 year | -0.8% | -990K shares |
| 3 years | +3.9% | +4.6M shares |
| 5 years | +38% | +33M shares |
| Available history | +51% | +40.7M shares |
UCB has 120M diluted shares, down 0.8% from a year ago, with $67M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $37.1M |
| Q4 2025 | $30.3M |
| Q3 2025 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q3 2021 | $10M |
UCB spent $67M buying back its own shares over the past year.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
UCB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.4x | Very low |
| Q3 2024 | 0.4x | Very low |
UCB has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
UCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.7 | Neutral |
| Stochastic | 78.3 | Neutral |
UCB's weekly RSI is 62 (neutral) and its Stochastic is 78 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over UCB on valuation relative to its sector.
UCB PE vs Financial Services Sector
| Metric | UCB | Sector median | Relative |
|---|---|---|---|
| PE | 31x | 13x | 137% above |
| PE % | 100 | 63 | 37 pts above |
UCB has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
UCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.5 | 5.1% above |
| 20 week MA | $35.5 | 4.9% above |
| 50 week MA | $34.0 | 9.6% above |
| 100 week MA | $32.1 | 16% above |
| 200 week MA | $29.8 | 25% above |
UCB has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
UCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.9 | $28.7 | -7.1% |
| 2021 | $28.7 | $34.4 | +20% |
| 2022 | $34.4 | $33.5 | -2.5% |
| 2023 | $33.5 | $29.3 | -13% |
| 2024 | $29.3 | $32.4 | +11% |
| 2025 | $32.4 | $32.3 | -0.2% |
| 2026 YTD | $32.3 | $37.3 | +15% |
UCB has the edge over BAC on returns for 2026, with the stronger performance.